Management of acute kidney disease in type 2 diabetes: the potential role of GLP-1 RAs and SGLT2-Is

Conflict of interest

KE has been member on advisory boards for Eli Lilly & Co., NovoNordisk, Lifescan, Roche, GSK, Bayer and has received honoraria from these activities; LDN has participated in the advisory boards for AstraZeneca and Bayer and has received honoraria for this activity; DG has no conflicts of interest to declare.

Ethical approval

Not applicable (no original data).

Informed consent to participate

Not applicable (no original data).

Comments (0)

No login
gif